Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia
| dc.contributor.author | Kostapanos, M. S. | en |
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Christogiannis, L. G. | en |
| dc.contributor.author | Bairaktari, E. T. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T16:56:34Z | |
| dc.date.available | 2015-11-24T16:56:34Z | |
| dc.identifier.issn | 1074-2484 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10455 | |
| dc.rights | Default Licence | - |
| dc.subject | hdl subfractions | en |
| dc.subject | paraoxonase-1 | en |
| dc.subject | lipoprotein-associated phospholipase a(2) | en |
| dc.subject | rosuvastatin | en |
| dc.subject | activating-factor-acetylhydrolase | en |
| dc.subject | coronary-heart-disease | en |
| dc.subject | lipoprotein subfractions | en |
| dc.subject | subpopulation profile | en |
| dc.subject | hypolipidemic drugs | en |
| dc.subject | phospholipase a(2) | en |
| dc.subject | human plasma | en |
| dc.subject | dense ldl | en |
| dc.subject | atorvastatin | en |
| dc.subject | cholesterol | en |
| dc.title | Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia | en |
| heal.abstract | Although the raising effect of rosuvastatin on high-density lipoprotein cholesterol is well-established, there is a paucity of data regarding the effect of this statin on the high-density lipoprotein subfraction phenotype. A total of 150 participants without evidence of cardiovascular disease were randomized to therapeutic lifestyle modification (nonstatin-treated group) or to therapeutic lifestyle modification plus rosuvastatin at 10 mg/d (RSV10 group) or 20 mg/d (RSV20 group). We assessed the effect of rosuvastatin on the cholesterol mass of high-density lipoprotein subfractions at baseline as well as after 12 weeks post-treatment. Rosuvastatin treatment close-dependently increased the high-density lipoprotein cholesterol (3.4% vs 5.3% in the RSV10 and RSV20 groups, respectively, P = .02). A dose-related rosuvastatin-induced increase in the cholesterol concentration of large high-density lipoprotein particles was also noted (by 11.4% in RSV10 group vs 22.0% in the RSV20 group, P = .01). Rosuvastatin treatment increases the high-density lipoprotein cholesterol by increasing the cholesterol mass only of the larger high-density lipoprotein particles in a dose-dependent manner. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | Doi 10.1177/1074248408331031 | - |
| heal.identifier.secondary | <Go to ISI>://000263489900001 | - |
| heal.identifier.secondary | http://cpt.sagepub.com/content/14/1/5.full.pdf | - |
| heal.journalName | Journal of Cardiovascular Pharmacology and Therapeutics | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2009 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: